43 filings
Page 2 of 3
6-K
vxgvtb300
30 Aug 22
Current report (foreign)
4:01pm
6-K
2wwkf27hpkdpbmd
19 Aug 22
Current report (foreign)
6:06am
6-K
pxg50g8t
11 Jul 22
Current report (foreign)
4:30pm
6-K
tgr 1dinoo2j3
17 Jun 22
Current report (foreign)
4:06pm
6-K
3pgv9imygp0h
10 Jun 22
Current report (foreign)
6:05am
6-K
ei5xckt8
9 May 22
Current report (foreign)
4:10pm
6-K
5g4qmwm4kyef0cwb
5 May 22
Current report (foreign)
6:04am
6-K
cgfs9uwbh crvl12r
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
6-K
vm75ma 2o
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
6-K
pjzom33gdn0b
1 Mar 22
Current report (foreign)
4:16pm
6-K
8gj91z9k9wfp zln
16 Feb 22
Current report (foreign)
4:01pm
6-K
vxz0z7tt
5 Jan 22
Current report (foreign)
5:24pm
6-K
jx1nvtk4fqj0wdfstqi2
22 Nov 21
Current report (foreign)
5:12pm
6-K
1krd7dy
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
qsi qmigyf6fom
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
fe49ea ae
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
xbfj 4sijoq
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
3v15mvmrjz7mliwp582
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
7176g
27 Aug 21
Current report (foreign)
4:10pm
6-K
rux5e2fa7 7mjbyj0d
16 Jun 21
Current report (foreign)
4:01pm